Home
  • English
  • Afrikaans (Afrikaans)
  • CONTACT US
  • +27 21 888 3000
  • info@remgro.com
MENUMENU
  • About
    Remgro
        • Our business
        • Group profile
        • Company history
        • Our business model
        • Understanding the business of Remgro
        • Key objectives and principal integrated risks
        • Leadership
        • Ethics hotline
  • Investor
    Centre
        • Salient features
        • Share statistics
        • Dividend history
        • Restructuring news
        • Share price information
        • Financial results and annual reports
        • SENS
        • Presentations
        • Calendar
        • IR contact
        • Listing Information
        • Shareholder information
        • Request an annual report
        • Events
  • Group
    Investments
        • Healthcare
        • Consumer products
        • Financial services
        • Infrastructure
        • Industrial
        • Diversified investment vehicles
        • Media
        • Portfolio investments
        • Social impact investments
        • Treasury and management services
  • ESG and
    sustainability
        • ESG and Sustainability Strategy Overview
        • Abridged Sustainability Report
        • Corporate Governance Report
        • Remuneration Report
        • Risk and Opportunities Management Report
        • Social and Ethics Committee Report
        • Corporate social investment
        • Charters and mandates
        • BBBEE Compliance Report
        • FTSE4Good Certificate
        • Our green head office
  • Media
    Centre
        • Media releases
        • Circulars
        • Media contact
        • Logo Library
        • Mediclinic offer

fees

Posted 11:26 am by remgrowp_GKfsl9 & filed under .

Latest results

  • Results
  • Press release
  • Presentation
  • Intrinsic net asset value
  • Headline earnings

PLAYBACK

Webcast:
services.themediaframe.com/links/remgro10043841.html

Latest news

  • Interim report – unaudited results for the six months ended 31 December 2022 and cash dividend declaration
    22 March 2023
  • Offer for Mediclinic

SENS Releases

Sustainability
Report 2022
Annual Financial
Statements 2022
Integrated Annual
Report 2022

View online report

Head Office
Millennia Park
16 Stellentia Avenue
Stellenbosch, 7600		 +27 21 888 3000
info@remgro.com
  • CAREERS
  • GROUP SITES

ETHICS HOTLINE 0800 222 536


Invenfin is the venture and growth capital division of Remgro

VISIT THE SITE >

2023 © Remgro Limited

E-mail Disclaimer | Terms of Use | Privacy Policy | PAIA | Site Map

  • About
    Remgro
    ▼
    • Our business
    • Group profile
    • Company history
    • Our business model
    • Understanding the business of Remgro
    • Key objectives and principal integrated risks
    • Leadership
    • Ethics hotline
  • Investor
    Centre
    ▼
    • Salient features
    • Share statistics
    • Dividend history
    • Restructuring news
    • Share price information
    • Financial results and annual reports
    • SENS
    • Presentations
    • Calendar
    • IR contact
    • Listing Information
    • Shareholder information
    • Request an annual report
    • Events
  • Group
    Investments
    ▼
    • Financial services
    • Healthcare
    • Consumer products
    • Industrial
    • Infrastructure
    • Media
    • Diversified investment vehicles
    • Portfolio investments
    • Social impact investments
    • Treasury and management services
  • ESG and
    sustainability
    ▼
    • ESG and Sustainability Strategy Overview
    • Corporate Governance Report
    • Risk and Opportunities Management Report
    • Remuneration Report
    • Social and Ethics Committee Report
    • Abridged Sustainability Report
    • Corporate social investment
    • Charters and mandates
    • BBBEE Compliance Report
    • FTSE4Good Certificate
    • Our green head office
  • Media
    Centre
    ▼
    • Mediclinic offer
    • Media releases
    • Circulars
    • Media contact
    • Logo Library